LOS ANGELES (Reuters) - Continued use of Rituxan cut by about 50 percent the risk that follicular lymphoma patients would have their cancer return, according to a late-stage study of the drug, which ...
The B-cell–depleting drug rituximab was associated with a twofold increased risk for infection in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment duration or ...
Please provide your email address to receive an email when new articles are posted on . A single, 500 mg dose of rituximab was associated with greater probability of minimal myasthenia gravis ...
In patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis treated with rituximab, risk factors for relapse differed by treatment phase; musculoskeletal involvement was ...
Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...
No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...
Modulation of lipid rafts (LR), p-glycoprotein (P-gp) and proinflammatory cytokines (PIC) with HMG-Co A reductase inhibitor simvastatin (SV) in chronic myelogenous leukemia (CML) patients with ...
Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line ...
AstraZeneca’s SOUNDTRACK-F1 study aims to improve on related risks seen with chemotherapy-including treatments in follicular ...
The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown. Among patients with relapsed or refractory follicular lymphoma (FL), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results